Blake Geren, MD
Ophthalmology · Fort Smith, ARNPI 1063448405
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 54.9% of the total. 2025 is the largest year on record at $1,070, 3.4 times the $312 reported in 2019.
Across 111 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Biotissue Holdings Inc.$464
- Bausch & Lomb Americas Inc.$209
- Sun Pharmaceutical Industries Inc.$102
- Alcon$90
- Bausch & Lomb, A Division Of Bausch Health US, LLC$70
- plus $266 from 7 others
What the payments were for
- Food & beverage$2,62198%
- Entertainment$422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $1,463 |
| Biotissue Holdings Inc. | 5 | $464 |
| Bausch & Lomb Americas Inc. | 10 | $209 |
| Sun Pharmaceutical Industries Inc. | 5 | $102 |
| Alcon | 5 | $90 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $70 |
| Oyster Point Pharma, Inc. | 3 | $65 |
| Optos, Inc. | 3 | $54 |
| Rxsight Inc | 2 | $45 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $41 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| Harrow Eye, LLC | 1 | $18 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,663 in reported general payments places this provider in the 85th percentile of 125 ophthalmology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 92 | $50,093 |
| RestasisCyclosporine | 40 | $39,550 |
| VyzultaLatanoprostene Bunod | 71 | $26,757 |
| RocklatanNetarsudil Mesylat/Latanoprost | 54 | $23,460 |
| RhopressaNetarsudil Mesylate | 49 | $18,994 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 68 | $17,870 |
| Brimonidine Tartrate | 369 | $14,443 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $13,571 |
| Alphagan PBrimonidine Tartrate | 36 | $12,590 |
| Prednisolone Acetate | 431 | $11,631 |
| Latanoprost | 1,139 | $8,447 |
| MoxifloxacinMoxifloxacin Hcl | 333 | $7,856 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 29 | $7,798 |
| Brinzolamide | 36 | $6,199 |
| Ketorolac Tromethamine | 309 | $5,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,463 | $115,805210 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $209 | $26,75771 claims |
| AlconSimbrinza | $90 | $17,87068 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax | $70 | $4,58412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 125 ophthalmology providers in Arkansas.
Other ophthalmology in Fort Smith
- Claire PriceFort Smith$3K
- Christopher RodriguezFort Smith$2K
- Chetan SoniFort Smith$2K
- Christopher GreerFort Smith$2K
- Randy EnnenFort Smith$1K
- Daniel SinesRogers$81K
- Mike McFarlandPine Bluff$63K
- Jennifer DoyleLittle Rock$38K
- James LinderMarion$18K
- Matthew MargolisJonesboro$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.